Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Vir Biotechnology, Inc. - Common Stock (NQ:VIR)

5.030 -0.040 (-0.79%)

Streaming Delayed Price Updated: 4:00 PM EDT, Aug 1, 2025 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	809,884
Open	5.000
Bid (Size)	4.880 (1)
Ask (Size)	5.650 (1)
Prev. Close	5.070
Today's Range	4.885 - 5.050
52wk Range	4.320 - 14.45
Shares Outstanding	133,976,538
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Vir Biotechnology Initiates Second Pivotal Trial in Its Global ECLIPSE Registrational Program for Chronic Hepatitis Delta

July 31, 2025

From Vir Biotechnology, Inc.

Via Business Wire

Vir Biotechnology Announces First Patient Dosed in Phase 1 Clinical Trial of EGFR-Targeting PRO-XTEN™ Dual-Masked T-Cell Engager VIR-5525 for the Treatment of Solid Tumors

July 24, 2025

From Vir Biotechnology, Inc.

Via Business Wire

Performance

YTD	-30.8%	-30.8%
1 Month	-7.0%	-7.0%
3 Month	-18.2%	-18.2%
6 Month	-49.6%	-49.6%
1 Year	-45.4%	-45.4%

More News

Earnings Scheduled For May 7, 2025

May 07, 2025

Via Benzinga

Earnings Outlook For Vir Biotechnology

May 06, 2025

Via Benzinga

5 Analysts Have This To Say About Vir Biotechnology

April 17, 2025

Via Benzinga

7 Analysts Have This To Say About Vir Biotechnology

February 28, 2025

Via Benzinga

Vir Biotechnology to Provide Corporate Update and Report Second Quarter 2025 Financial Results on August 6, 2025

July 22, 2025

From Vir Biotechnology, Inc.

Via Business Wire

12 Health Care Stocks Moving In Friday's After-Market Session

July 11, 2025

Via Benzinga

Where Vir Biotechnology Stands With Analysts

July 11, 2025

Via Benzinga

Vir Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025

May 28, 2025

From Vir Biotechnology, Inc.

Via Business Wire

Earnings Scheduled For February 26, 2025

February 26, 2025

Via Benzinga

Vir Biotechnology Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)

May 22, 2025

Via Benzinga

Vir Biotechnology to Participate in TD Cowen 6th Annual Oncology Innovation Summit

May 20, 2025

From Vir Biotechnology, Inc.

Via Business Wire

Vir Biotechnology to Participate in Bank of America Securities 2025 Healthcare Conference

May 12, 2025

From Vir Biotechnology, Inc.

Via Business Wire

Marriott International To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Monday

May 12, 2025

Via Benzinga

Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study

May 09, 2025

From Vir Biotechnology, Inc.

Via Business Wire

Vir Biotechnology Provides Corporate Update and Reports First Quarter 2025 Financial Results

May 07, 2025

From Vir Biotechnology, Inc.

Via Business Wire

Vir Biotechnology to Provide Corporate Update and Report First Quarter 2025 Financial Results on May 7, 2025

April 30, 2025

From Vir Biotechnology, Inc.

Via Business Wire

Vir Biotechnology to Present Latest Clinical Data in Hepatitis Delta and B Programs at the European Association for the Study of the Liver (EASL) Congress 2025

April 24, 2025

From Vir Biotechnology, Inc.

Via Business Wire

Vir Biotechnology Enrolls First Patient in Phase 3 ECLIPSE Registrational Program for Chronic Hepatitis Delta

March 13, 2025

From Vir Biotechnology, Inc.

Via Business Wire

Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

February 26, 2025

From Vir Biotechnology, Inc.

Via Business Wire

Vir Biotechnology to Participate in TD Cowen 45th Annual Health Care Conference

February 19, 2025

From Vir Biotechnology, Inc.

Via Business Wire

Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025

February 12, 2025

From Vir Biotechnology, Inc.

Via Business Wire

Morgan Stanley Doubles Vir Biotechnology Price Forecast - Here's Why

January 10, 2025

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

January 08, 2025

Via Benzinga

Frequently Asked Questions

Is Vir Biotechnology, Inc. - Common Stock publicly traded?

Yes, Vir Biotechnology, Inc. - Common Stock is publicly traded.

What exchange does Vir Biotechnology, Inc. - Common Stock trade on?

Vir Biotechnology, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Vir Biotechnology, Inc. - Common Stock?

The ticker symbol for Vir Biotechnology, Inc. - Common Stock is VIR on the Nasdaq Stock Market

What is the current price of Vir Biotechnology, Inc. - Common Stock?

The current price of Vir Biotechnology, Inc. - Common Stock is 5.030

When was Vir Biotechnology, Inc. - Common Stock last traded?

The last trade of Vir Biotechnology, Inc. - Common Stock was at 08/01/25 04:00 PM ET

What is the market capitalization of Vir Biotechnology, Inc. - Common Stock?

The market capitalization of Vir Biotechnology, Inc. - Common Stock is 673.90M

How many shares of Vir Biotechnology, Inc. - Common Stock are outstanding?

Vir Biotechnology, Inc. - Common Stock has 674M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.